Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2022 09:29 ET | Source: Statera Biopharma

Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
March 22, 2022 07:38 ET | Source: Statera Biopharma

CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
March 21, 2022 16:50 ET | Source: Statera Biopharma

Statera Biopharma Announces Proposed Underwritten Public Offering

FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
March 08, 2022 16:15 ET | Source: Statera Biopharma

Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021

FORT COLLINS, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
March 07, 2022 07:30 ET | Source: Statera Biopharma

Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform

In collaboration with MolSoft, ImQuest, a Statera company, is investigating new, optimized compositions incorporating desirable elements of STAT-200 FORT COLLINS, Colo., March 07, 2022 (GLOBE...
March 02, 2022 09:08 ET | Source: Statera Biopharma

CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Statera Biopharma, Inc. (Nasdaq: STAB), please note an additional sentence has...
March 02, 2022 07:30 ET | Source: Statera Biopharma

Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune...
February 25, 2022 07:32 ET | Source: Statera Biopharma

Statera Biopharma Announces Changes to Board of Directors

—Satish Chandran of Lays Sciences and Physis Pharma, Inc. to join Board of Directors as Steve Barbarick transitions to advisory role— FORT COLLINS, Colo., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Statera...
February 22, 2022 07:51 ET | Source: Statera Biopharma

Statera Biopharma Announces Preliminary Revenue and Financial Results of Fiscal Year ‘21

FORT COLLINS, Colo., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
February 15, 2022 09:04 ET | Source: Statera Biopharma

Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn’s Disease

STAT-201 is being developed as a novel, immune-modulation therapy for treating Crohn’s Disease Phase 3 trial expected to begin in second quarter 2022 FORT COLLINS, Colo., Feb. 15, 2022 (GLOBE...